VolitionRX Limited

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Volition RX Limited's full year 2022 earnings conference call. During today's presentation, all parties will be in listen-only mode. Following the presentation, the conference call will be open for questions. If you have a question, please press the star key followed by the number one on your touchtone phone. If you would like to withdraw your question, press the star key followed by the number two. If you're using speaker equipment, please lift the handset before making your selections. This conference is being recorded today, March 16th, 2023. I'd now like to turn the conference call over to Scott Powell, Executive Vice President of Investor Relations. Please go ahead.

Thank you and welcome everyone to today's earnings conference call for VolitionRx Limited. This call will cover Volition's financial and operating results for the full year 2022, along with a discussion of our recent activities, and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question and answer session. Also on our call today are Mr. Cameron Reynolds, President and Group Chief Executive Officer, Mr. Terry Cuse, Group Chief Financial Officer, and Dr. Tom Butera, Chief Executive Officer of our Volition Veterinary Subsidiary. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, These statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call. I'd now like to turn the call over to our President and Chief Executive Officer, Mr. Cameron Reynolds. Cameron?

Thanks, Scott, and thank you everyone for joining Volition's full year 2022 earnings call today. We especially appreciate your time given the busy earnings call season. 2022 was a transformational year for Volition. After 12 years in operation, we have successfully transitioned from a company solely focused on research and development to an organization that has also commercial products. Volition is powered by New Cube, our cutting-edge nucleosomics platform which has enabled the development of all of our product pillars and is the foundation of the company. I am so proud of the hard work, expertise, and commitment of our team and what we've achieved together. Given this is our full fiscal year result, we will commence the fall with our Group Chief Financial Officer, Terry Hughes, for moving on to Dr. Tom Butera, Chief Executive Officer of VolitionVac. for an update on the rollout of NICU VET via our global supply and licensing agreements. And finally, I will provide an update on the great progress the team have been making with regards to another one of our key pillars, NICU NET, as well as a brief update on NICU Cancer and NICU Capture. Without further ado, I'll hand you across to Tarek for the financial report.